MTOR and melanoma: In a new phase II study of everolimus in patients with advanced melanoma characterized by mTOR mutations [229]; the results revealed that patients with mTOR-mutated melanoma respond significantly better, whereas mTOR inhibitors have a limited effect in patients with unselected melanoma.